Market Research Report
Asia Pacific Clinical Nutrition Market By Route of Administration By Application By Country, Industry Analysis and Forecast, 2020 - 2026
|Published by||KBV Research||Product code||941652|
|Published||Content info||104 Pages
Delivery time: 1-2 business days
|Asia Pacific Clinical Nutrition Market By Route of Administration By Application By Country, Industry Analysis and Forecast, 2020 - 2026|
|Published: May 31, 2020||Content info: 104 Pages||
Asia Pacific Clinical Nutrition Market By Route of Administration (Oral, Enteral and Parenteral) By Application (Cancer, Neurological Diseases, Gastrointestinal Disorders, Metabolic Disorders and Other Applications) By Country, Industry Analysis and Forecast, 2020 - 2026.
The Asia Pacific Clinical Nutrition Market would witness market growth of 8.2% CAGR during the forecast period (2020-2026).
Increased prevalence of chronic disorders, and increased numbers of patients using advanced clinical nutrition products, leading towards the growth of the clinical nutrition industry. Increased government R&D investments in health care are also some of the key factors driving the global market for clinical nutrition. The clinical nutrition industry is however hindered by a lack of knowledge and strict regulations. In addition, increased progress in clinical nutrition is expected to offer profitability to global clinical nutrition market players and the growth of various growth opportunities for clinical nutritional products in emerging countries.
Asia-Pacific is expected to grow at the highest growth over the forecast period. The key factors contributing to the growth of the Asia-Pacific clinical nutrition market include a rise in the prevalence of metabolic disorders, an expansion in the geriatric population in the Asia-Pacific region, as well as extensive healthcare spending. The prevalence of diabetes in China is also growing rapidly, which is a major factor in obesity. The actual number of patients diagnosed with metabolic disorders has increased over the last decade, increasing the number of patients diagnosed in the Asia Pacific region.
Most metabolic syndromes lead to situations where the body cannot synthesize non-essential molecules, such as vitamins, amino acids, and several molecules involved in metabolic pathways. Most of these conditions can only be managed with the addition of one or two nutrients. All of these factors are helping the growth of the market. There are, however, few factors that may restrict the market growth.
Based on Route of Administration, the market is segmented into Oral, Enteral and Parenteral. Based on Application, the market is segmented into Cancer, Neurological Diseases, Gastrointestinal Disorders, Metabolic Disorders and Other Applications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, B. Braun Melsungen AG, Baxter International, Inc., Pfizer, Inc., Nestle S.A., Lonza Group AG, BASF SE, Ajinomoto Co., Inc., Perrigo Company PLC, and Hero Nutritionals, Inc.
By Route of Administration
Unique Offerings from KBV Research: